Skip to content

Nicorandil-CKD study

Nicorandil-CKD study - Nicorandil-CKD study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008544
Enrollment
250
Registered
2012-07-26
Start date
2008-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

Patient were divided into 2 groups, the saline group and Nicorandil group. In both group, saline was infused 1ml/kg/h 4 hours prior to PCI and after 20hours. To Nicolandil group, Nicolandil was infus

Sponsors

Department of Cardiology, Respirology, and Nephrology, Gifu University Graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who subsequently undergo PCI and who had higher cystatin C level than normal cyctatin C level(male 0.95mg/L, female 0.8mg/L).

Exclusion criteria

Exclusion criteria: heart failure acute coronary syndrome pediatrics hemodialysis

Design outcomes

Primary

MeasureTime frame
Incidences of CIN during 1 month

Secondary

MeasureTime frame
Percent rise in serum creatinine Percent rise in estimated GFR

Countries

Japan

Contacts

Public ContactKazuhiko Nishigaki

Gifu university hospital The second departure of internal medicine

nissy@gifu-u.ac.jp058-328-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026